Skip to content

Clinical study to check the effectiveness and safety of AphtoFix® Mouth Ulcer Cream in subjects suffering from mouth ulcer.

A Phase IV, Monocentric, Open Label, Clinical Study to Evaluate the Efficacy and Safety of AphtoFix® Mouth Ulcer Cream Manufactured by Bonyf AG in Subjects Suffering from Mouth Ulcer.

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2014/08/004918
Enrollment
20
Registered
2014-08-22
Start date
Unknown
Completion date
Unknown
Last updated
2025-08-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K928- Other specified diseases of the digestive system

Interventions

Intervention1: AphtoFix®: Cream will be applied by squeezing a small amount of cream on the tip of the finger and to be applied on affected area using a swiping action to ensure that the cream covers

Sponsors

Bonyf AG
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Male or female subjects with 18 – 65 years of age (both inclusive). 2. Subjects having mouth ulcer size >2 mm in locations for easily accessible for evaluation and treatment. 3. Subject with time of onset of mouth ulceration within 48 hours. 4. Subject who agreed, not to use any other medication to treat mouth ulcer during study period. 5. Subject willingness to comply with the study schedule and procedures. 6. Subject / legally acceptable representative (LAR) of subject willing to sign and date written informed consent to participate in the study. However, if the subject/LAR of subject is illiterate, the impartial witness would sign the ICF.

Exclusion criteria

Exclusion criteria: 1. Subjects with a history of allergy for content present in AphtoFix® 2. Subjects with any invasive dental procedures within 2 weeks prior to screening visit. 3. History of uncontrolled chronic disease (e.g. chronic liver disease, chronic renal disease) 4. Use of any other medication to treat mouth ulcer in current episode. 5. Participation in any other clinical study during last 30 days. 6. Subject with any condition which in the opinion of the investigator makes the subject unsuitable for inclusion. 7. Subject is a female who is pregnant or willing to get pregnant, not ready to use contraceptive measures during the trial period, or is breast feeding.

Design outcomes

Primary

MeasureTime frame
- Ulcer size reduction. - Reduction in number of ulcers. - Pain reduction by assessing pain intensity.Timepoint: 14 days

Secondary

MeasureTime frame
- Duration of ulcer (Days need for complete healing). - Number and frequency of application. - Quality of life evaluation using mouth ulcer QOL Questionnaire.Timepoint: 14 Days

Countries

India

Contacts

Public ContactDr Milan Satia

Ethicare Clinical Trial Services

milansatia@ethicare-cro.com09825585119

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026